HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

THE MODERN STRATEGY FOR THE TREATMENT OF BASAL CELL CARCINOMA OF THE HEAD AND NECK

Download full text PDF
Issue: 
12
Year: 
2017

А. Samulenko, A. Mordovsky, A. Polyakov, Candidate of Medical Sciences P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia

Basal cell carcinoma (BCC) is the most common tumor of the skin. The main goal of treatment is complete tumor removal with less obvious functional and cosmetic losses. The choice of treatment largely depends on the risk of relapse, which is associated with the presence or absence of aggressive clinical and histopathological signs. The authors have analyzed 233 cases of BCC treatment, including 127 and 106 primary and recurrent BCC cases, respectively. The recurrence rate of primary BCC after surgical treatment in the patients of the authors’ department was 0.8%.

Keywords: 
oncology
basal cell skin cancer
relapse risks
basal cell carcinoma (BCC) treatment
recurrent BCC
Hedgehog pathway inhibitors



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Zlokachestvennye novoobrazovanija v Rossii v 2016 g. (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj / M.: MNIOI im. P.A. Gertsena – filial FGBU «FMITs im. P.A. Gertsena» Minzdrava Rossii, 2016; 250 s.
  2. Goppner D., Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease // J. Skin Cancer. – 2011; 2011: 650258.
  3. Reifenberger J., Wolter M., Knobbe C. et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas // Br. J. Dermatol. – 2005; 152 (1): 43–51.
  4. Heffelfinger C., Ouyang Z., Engberg A. et al. Correlation of Global MicroRNA Expression With Basal Cell Carcinoma Subtype // PabMedCenteral J. List. G3 (Bethesda). – 2012; 2 (2): 279–86. URL: https://www.ncbi.nlm.nih.gov/pubmed/22384406
  5. Dandurand M. et al. Management of basal cell carcinoma in adults Clinical practice guidelines // Eur. J. Dermatol. – 2006; 16 (4): 394–401.
  6. Savoia P., Deboli T., Previgliano A. et al. Usefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell Carcinoma // Intern. J. Mol. Sci. – 2015; 16 (10): 23300–17. DOI: doi:10.3390/ijms161023300.
  7. Puig S., Berrocal A. Management of high-risk and advanced basal cell carcinoma // Clin. Transl. Oncol. – 2015; 17 (7): 497–503.
  8. Sekulic A., Migden M., Lewis K. et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC // J. Am. Acad. Dermatol. – 2015; 72 (6): 1021–6.
  9. Basset-Seguin N., Hauschild A., Grob J. et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial // Lancet Oncol. – 2015; 16 (6): 729–36.
  10. Dréno B., Kunstfeld R., Hauschild A. et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial // Lancet Oncol. – 2017; 18: 404–12.